LONDON, ONTARIO, Oct. 20, 2009 (Marketwire) -- Sernova Corp. (TSX VENTURE:SVA) is pleased to provide a summary of results of islet transplantation studies related to its Cell Pouch System(TM) and Sertolin(TM) technologies presented at the joint conference of the International Pancreas and Islet Transplant Association and the International Xenotransplantation Association held in Venice, Italy from October 12 - 16.
Sernova scientists presented seven abstracts, three of which were highlighted in oral presentations. These data serve to validate the efficacy of Sernova's prototype proprietary Cell Pouch System(TM) and Sertolin(TM) technologies in vivo.
The Cell Pouch System(TM) is a revolutionary improvement over the current practice of injecting cells into blood vessels. It is a chamber which becomes a vascularised organ-like structure when placed in the body and provides the microcirculation essential to early function and long-term survival of cells. The first application is diabetes where the Cell Pouch System(TM) for islet transplantation is expected to prevent the instant blood-mediated inflammatory reaction (IBMIR) believed to rapidly destroy over 90% of implanted islets placed into the portal vein and eliminate islet-induced blood clotting and liver thrombosis. Overall the data presented provide in vivo validation of Sernova's Cell Pouch System(TM) for cell transplantation and has aided in the design and manufacture of a human-scaled device which is currently being tested in a large animal model of diabetes. The National Research Council of Canada is providing Sernova with a financial contribution of up to $486,000 to support these studies.
The Company's Sertolin(TM) technology is a novel combination therapy using Sertoli cells to provide an immune-protected environment for cell transplant which may reduce or eliminate the need for immunosuppressant agents. The company reported that without immunosuppressive drugs, diabetic rats transplanted with porcine islets showed a strong IgG-mediated rejection of islets which were completely destroyed by the 14 day evaluation time point. To eliminate or reduce the dose of toxic immunosuppressant agents, porcine Sertoli cells known to naturally protect sperm cells from immune attack were co-transplanted with porcine islets into the kidney capsule. It was shown that the co-transplant using Sertoli cells from sexually mature porcine and porcine islets significantly inhibited the IgG immune response with islets showing long-term robust production of insulin at 70 and 180 days post-implantation.
